Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Rhea-AI Summary

Alpha Tau (Nasdaq: DRTS) announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference on March 18, 2026 from 10:00–10:30 AM ET. The presentation is virtual and Mr. Levy is available for one‑on‑one investor meetings scheduled through Sidoti representatives.

Key Figures

Conference dates: March 18–19, 2026 Presentation date: March 18, 2026 Presentation time: 10:00–10:30AM ET +5 more

8 metrics

Conference dates March 18–19, 2026 Sidoti Virtual Small Cap Conference schedule

Presentation date March 18, 2026 Alpha Tau company presentation

Presentation time 10:00–10:30AM ET Sidoti conference presentation slot

Current price $7.17 Pre-news trading level

52-week high $8.60 Upper end of 52-week trading range

52-week low $2.30 Lower end of 52-week trading range

Market cap $594,291,098 Equity value before conference news

Price change 24h 2.87% Move ahead of Sidoti presentation

Market Reality Check

Price: $7.17 Vol: Volume 151,536 is below t...

low vol

$7.17 Last Close

Volume Volume 151,536 is below the 20-day average of 302,505, suggesting limited trading interest ahead of the conference. low

Technical Price at $7.17 is trading above the 200-day MA of $4.51, indicating a pre-existing upward trend before this conference news.

Peers on Argus

DRTS is up 2.87% while biotech peers ADCT (-5.28%), ALDX (-12.05%), AUTL (-2.04%...

DRTS is up 2.87% while biotech peers ADCT (-5.28%), ALDX (-12.05%), AUTL (-2.04%), IMRX (-7.68%) and TECX (-3.95%) are all down, pointing to a stock-specific move rather than a sector-wide trend.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Earnings and update	Positive	+1.9%	Full-year 2025 results and corporate update with regulatory and clinical progress.
Feb 24	Japan approval	Positive	+1.2%	Japanese marketing approval for Alpha DaRT in head and neck cancer.
Jan 29	Shareholder letter	Positive	-4.7%	Letter outlining five concurrent U.S. trials and upcoming milestones.
Jan 06	Clinical data update	Positive	+11.9%	Positive pancreatic cancer Alpha DaRT data presented at ASCO GI 2026.
Jan 05	FDA PMA module	Positive	+8.1%	First PMA module submission to FDA for recurrent cutaneous SCC.

Pattern Detected

Recent clinical, regulatory, and earnings updates have mostly seen positive price reactions, with one divergence on a strategic update.

Recent Company History

Over recent months, Alpha Tau has reported several milestones, including Japanese marketing approval for Alpha DaRT®, progress on five concurrent U.S. clinical trials, and a first PMA module submission to the FDA for recurrent cSCC. Clinical data at ASCO GI 2026 showed notable ORR and DCR figures in pancreatic cancer. Full-year 2025 results highlighted cash of $76.9M and a $42.6M net loss. Against this backdrop, today’s Sidoti small-cap conference presentation reflects continued investor-relations outreach following regulatory and clinical momentum.

Market Pulse Summary

This announcement highlights Alpha Tau’s participation in the Sidoti Virtual Small Cap Conference on...

Analysis

This announcement highlights Alpha Tau’s participation in the Sidoti Virtual Small Cap Conference on March 18–19, 2026, with a company presentation scheduled from 10:00–10:30AM ET. It follows recent regulatory approval in Japan, positive clinical data, and progress toward FDA PMA submission. Investors may monitor how management frames its strategy, commercialization plans, and trial timelines, using this appearance as another checkpoint in the company’s broader clinical and regulatory trajectory.

Key Terms

alpha-radiation

1 terms

alpha-radiation medical

"the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®"

Alpha radiation is a type of ionizing radiation made of heavy, positively charged particles (two protons and two neutrons) emitted by certain radioactive materials; it travels only a short distance and can be stopped by paper or skin but is dangerous if ingested or inhaled. Investors should care because alpha-emitting materials influence regulatory oversight, handling and disposal costs, workplace safety liabilities, and the value of medical or energy projects that use or produce radioactive substances — like a heavy but short‑ranged cannonball that creates big local effects where it lands.

AI-generated analysis. Not financial advice.

JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026.

Event:	Sidoti Virtual Small Cap Conference
Format:	Company Presentation
Date:	March 18, 2026
Time:	10:00 – 10:30AM ET
Location:	Virtual

Mr. Levy will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule.

About Alpha Tau Medical Ltd. 

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT^®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Investor Relations Contact:
IR@alphatau.com

FAQ

When will Alpha Tau (DRTS) present at the Sidoti Virtual Small Cap Conference?

Alpha Tau will present on March 18, 2026, 10:00–10:30 AM ET. According to the company, CFO Raphi Levy will deliver the company presentation and be available for 1x1 investor meetings via Sidoti scheduling.

How can investors meet Alpha Tau CFO Raphi Levy at the Sidoti conference (DRTS)?

Investors can schedule 1x1 meetings through their Sidoti representative. According to the company, Raphi Levy will be available for one‑on‑one investor meetings during the virtual conference on March 18–19, 2026.

Where can I watch Alpha Tau's (DRTS) presentation at the Sidoti Virtual Small Cap Conference?

The presentation is being held in a virtual format on March 18, 2026 at 10:00 AM ET. According to the company, attendees should follow Sidoti conference access instructions or contact their Sidoti representative to join.

What topics will Alpha Tau (DRTS) cover in the Sidoti conference presentation?

The announcement states a company presentation by CFO Raphi Levy but gives no detailed agenda topics. According to the company, the session will cover corporate updates and investor engagement during the 30‑minute virtual presentation.

Is Alpha Tau's Sidoti presentation (DRTS) open to the public or by appointment?

The presentation is virtual and open via Sidoti conference access, while 1x1 meetings require scheduling through Sidoti representatives. According to the company, public attendance follows Sidoti registration and private meetings are by appointment.